Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Zacks Investment Research7/1/2026Positive
ACET
Adicet Bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$86.47M
P/E Ratio
—
EPS
$-14.89
Beta
1.59
52W High
$17.44
52W Low
$6.01
50-Day MA
$8.15
200-Day MA
$9.02
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.82
About Adicet Bio Inc
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $24.99M |
| EBITDA | $-107.76M |
| Operating Margin | 0.00% |
| Return on Equity | -72.20% |
| Return on Assets | -39.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $13.03 |
| Price-to-Book | 0.60 |
| Price-to-Sales (TTM) | 9.72 |
| EV/Revenue | 2.139 |
| EV/EBITDA | -1.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $9.35M |
| Float | $7.43M |
| % Insiders | 1.08% |
| % Institutions | 63.36% |
Historical Volatility
HV 10-Day
63.55%
HV 20-Day
54.57%
HV 30-Day
70.61%
HV 60-Day
74.47%
HV Rank
40.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($34.83 target)
6
BuyLatest News
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
Adicet Bio NASDAQ: ACET outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company's focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune disease and oncology.
MarketBeat6/4/2026Positive
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Zacks Investment Research5/28/2026Negative
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 319.6% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research5/25/2026Positive
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York. Details of the event are as follows: Date: Thursday, June 4, 2026 Time: 7:35a.m. ET The.
Business Wire5/14/2026Neutral
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2026. “Adicet is approaching a key inflection point as we prepare to report Phase 1 data for prula-cel in mid-year 2026, including data from at least 20 LN and SLE patients with a minimum.
Business Wire5/13/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026